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What’s new? 
• This study is the first to explore the gut microbiota in patients with Type 1 diabetes, 
but who otherwise have good glycaemic control and high physical fitness. 
• The gut microbiota from people with Type 1 diabetes and good glycaemic control and 
high physical fitness was comparable with that from matched healthy controls without 
diabetes. 
 
Abstract 
Aim  Type 1 diabetes is the product of a complex interplay between genetic susceptibility 
and exposure to environmental factors. Existing bacterial profiling studies focus on people 
who are most at risk at the time of diagnosis; there are limited data on the gut microbiota of 
people with long-standing Type 1 diabetes. This study compared the gut microbiota of 
patients with Type 1 diabetes and good glycaemic control and high levels of physical-fitness 
with that of matched controls without diabetes. 
Methods  Ten males with Type 1 diabetes and ten matched controls without diabetes were 
recruited; groups were matched for gender, age, BMI, peak oxygen uptake (VO2max), and 
exercise habits. Stool samples were analysed using next-generation sequencing of the 16S 
rRNA gene to obtain bacterial profiles from each individual. Phylogenetic investigation of 
communities by reconstruction of unobserved states (PICRUSt) was implemented to predict 
the functional content of the bacterial operational taxonomic units. 
Results  Faecalibacterium sp., Roseburia sp. and Bacteroides sp. were typically the most 
abundant members of the community in both patients with Type 1 diabetes and controls, and 
were present in every sample in the cohort. Each bacterial profile was relatively individual 
and no significant difference was reported between the bacterial profiles or the Shannon 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
diversity indices of Type 1 diabetes compared with controls. The functional profiles were 
more conserved and the Type 1 diabetes group were comparable with the control group. 
Conclusions  We show that both gut microbiota and resulting functional bacterial profiles 
from patients with long-standing Type 1 diabetes in good glycaemic control and high 
physical fitness levels are comparable with those of matched people without diabetes. 
 
Introduction 
Type 1 diabetes is the product of a complex interplay between genetic susceptibility and 
exposure to environmental factors [1]. Environmental exposure has long been implicated in 
the pathogenesis of the disease and now, with decades of evidence mapping an increased rate 
of incidence, it is clear that disease progression occurs at a rate for which genetic change 
alone cannot be solely accountable [2]. 
Previous research has shown that the gut microbiota, which is the collection of 
microorganisms colonizing the gut, has important roles in the disease [3–5]. Germ-free 
mouse models of Type 1 diabetes may acquire the disease at higher rates, but this has been 
challenged with no significant differences between germ-free and colonized mice [6]. In the 
same study, a Gram-positive organism was isolated that reduced the incidence of the disease. 
Administering ‘probiotic’ (live microorganisms which confer health benefits) to mouse 
models further demonstrated the potential of intervention targeting the gut microbiota to 
reduce disease incidence [6]. Antibiotic administration earlier in life may also predispose 
patients to Type 1 diabetes through modulation of the gut microbiota, and certain antibiotic 
combinations have recently been found to increase diabetes risk [7], although in mice the 
incidence was reduced with vancomycin from birth to weaning [8]. 
Research in children has shown that the gut microbiota in Finish people with Type 1 diabetes 
had greater Bacteroidetes relative to Firmicutes and reduced overall diversity [9]. More 
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recently in a Spanish cohort, people with Type 1 diabetes had an increased abundance of 
Clostridium, Bacteroides and Veillonella, and a reduced abundance of Bifidobacterium and 
Lactobacillus compared with controls [10]. Interestingly, the latter two organisms are 
regarded as beneficial and have been used extensively as probiotic candidates. Overall, these 
findings indicate that interactions between the intestinal microbiota and the innate immune 
system are critical for disease development [9,11]. However, Type 1 diabetes has a wide 
spectrum of severity and these studies tend to focus on people at who are most at risk at the 
time of diagnosis. Thus, an important knowledge gap remains in the literature regarding the 
status of people in adulthood with long-standing diabetes. Moreover, there are limited data 
examining such individuals who are intensively managed, demonstrating good glycaemic 
control and high levels of physical fitness. 
This study seeks to explore the gut microbiota in patients with Type 1 diabetes and good 
glycaemic control and high levels of physical fitness, matched to people without diabetes. 
Although the gut microbiota potentially contributes to the onset of Type 1 diabetes, we aimed 
to determine whether active patients with long-term Type 1 diabetes are able to develop a gut 
microbiome comparable with that of healthy controls or if important differences persist long 
after diabetes onset. 
 
Materials and Methods 
 
Participant recruitment and preliminary testing 
Fully informed written consent was obtained from all individuals following the study’s 
approval from National Health Service NRES Committee – Tyne and Wear South. 
Participants attended the Newcastle National Institute for Health Research Clinical Research 
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Facility to establish peak cardiorespiratory parameters during the completion of an 
incremental–maximal treadmill running protocol, as previously described [12]. Participants 
provided stool material on tissue paper that was deposited in a sterile falcon tube and stored 
at –80°C until processing. Tissue paper was sterilized under UV and a negative control 
sample of toilet paper was also carried out. 
Type 1 diabetes eligibility criteria consisted of being aged between 18 and 35 years, a 
duration of diabetes > 5 years, and an HbA1c < 64 mmol/mol (8.0%). In addition, patients 
with Type 1 diabetes were required to be absent of diabetes-related complications, other than 
mild–background retinopathy, not receiving any medication other than insulin (assessed 
against recent medical notes), and regularly and consistently undertaking exercise 
(participating in aerobic-based exercise for a minimum of 30 min at a time, at least three 
times per week). Ten males with Type 1 diabetes were recruited [aged 27 ± 2 years, BMI 
23.5 ± 0.7 kg/m2, peak oxygen uptake (VO2max) 51.3 ± 2.2 ml/kg/min, duration of diabetes 
12 ± 2 years, HbA1c 54.5 ± 2.1 mmol/mol (7.1 ± 0.4%)]. Patients were treated with a basal–
bolus regimen composed of long-acting insulin glargine (n = 8) or detemir (n = 2), and rapid-
acting insulin aspart. Eligibility criteria for controls without diabetes consisted of being 
between 18 and 35 years, and regularly and consistently undertaking exercise. Ten males 
without diabetes (controls) were recruited (aged 27 ± 2 years, BMI 22.4 ± 0.8 kg/m2, VO2max 
50.9 ± 1.2 ml/kg/min). The Type 1 diabetes and control groups were matched for age, fitness 
and BMI (P > 0.05). Both groups were habitually consuming a predominantly carbohydrate-
rich diet (> 60% carbohydrate) assessed via 24-h recall. Study demographics are summarized 
in Table 1. 
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16S rRNA gene bacterial profiling 
Participants were provided three sections of toilet paper from the same roll that had all 
undergone UV sterilization. Following excrement, the participants used the toilet paper once, 
the soiled tissue was then collected in sterile universal tubes. Nucleic acid extraction of stool 
was carried out on a section of the soiled toilet paper using the PowerLyzer™ PowerSoil® 
DNA Isolation Kit (MO BIO Inc., Carlsbad, CA, USA) in accordance with the 
manufacturer’s instructions. Bacterial profiling utilized the 16S rRNA gene targeting variable 
region 4 and was carried out by NU-OMICS (Northumbria University, Newcastle-upon-
Tyne, UK) based on the Schloss wet-lab MiSeq SOP and resulting. Raw fastq data were 
processed using Mothur (v. 1.31.2) as described previously [13]. Briefly, combined reads 
were trimmed to 275 reads with 0 ambiguous bases. Chimeric sequences were detected by 
Chimera.uchime and removed from downstream analysis. Alignment was generated via the 
Silva v4 database [14] and Chloroplast, Mitochondria, unknown, Archaea and Eukaryota 
linages were removed from the analysis. In total, 5 165 964 reads were generated from the 20 
samples. Sequences were deposited in MG-RAST under the accession numbers 4603090.3–
4603109.3. 
 
Statistical analysis 
Data were normalized by subsampling and rarefying all samples to 104 142 reads. The data 
were automatically transformed and analysed by principal coordinate analysis (PCA) using 
SIMCA 13.0 (Umetrics, Stockholm, Sweden) [15]. The community structure between the 
Type 1 diabetes and control groups was analysed by Parsimony and weighted UniFrac 
analysis [16]. Significant operational taxonomic unit (OTUs) were classified by the metastats 
function in Mothur using 1000 permutations with multiple hypothesis testing correction [17]. 
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Phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) 
was implemented to predict functional content of the bacterial OTUs [18]. 
 
Results 
The number of reads used in the subsampling (104 142) facilitated robust coverage of the gut 
microbiota of each individual in the cohort. No significant difference was found between the 
Type 1 diabetes and control groups using Parsimony (P = 0.309) and weighted UniFrac 
(P = 0.107). Faecalibacterium sp., Roseburia sp. and Bacteroides sp. were typically the most 
abundant members of the community in both the Type 1 diabetes and control groups, and 
were present in every sample in the cohort (Fig. 1). Levels of Bacteroides sp. tended to be 
higher in the control group (P = 0.06) and Bifidobacterium sp. tended to be higher in the 
Type 1 diabetes group (P = 0.08), but neither was significant. 
The bacterial profiles of the patients with Type 1 diabetes were comparable with those of the 
control group with no distinct clusters based on the bacterial profiles (Fig. 2A). To account 
for potential false negatives resulting from some patients with Type 1 diabetes, where HbA1c 
was outside the range for truly excellent control, further ordination analysis was conducted by 
stratifying Type 1 diabetes by HbA1c by > 53 mmol/mol or < 53 mmol/mol. PCA with this 
classification showed no distinct clustering based on the overall bacterial community, with 
resulting partial least squares discriminant analysis (PLS-DA) predictive (Q) scores of –0.106 
in > 53 mmol/mol and 0.022 in < 53 mmol/mol, where scores of > 0.5 represent significant 
differences and predictively between the groups (Fig. S1). Only 17 OTUs from a total of 
3062 were found to be significantly different between the groups (Table 2). Actinomyces sp. 
(OTU00428) was the most significant OTU (P = 0.008) in the Type 1 diabetes group and this 
was most associated with the Type 1 diabetes group in the PLS-DA loadings plot (Fig. 2B). 
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However, this OTU was detected in all but two participants (both from the control group) and 
only compromised of 62 reads from a total of 2 082 840 (0.003%), where 49 reads were from 
patients with Type 1 diabetes and 13 reads were from controls. No significant difference 
(P = 0.344) was found in the Shannon diversity index (H') between each group. The average 
Type 1 diabetes H' was 3.37 (range 2.16–3.92), whereas the control H' was 3.13 (range 2.62–
4.49). 
PICRUSt was implemented to predict functional content of the bacterial OTUs. This showed 
that despite the relatively large variation in the bacterial community between individuals, the 
functional profiles were much more comparable (Fig. 3). Functional profiles from the Type 1 
diabetes group were comparable to that of the control group. 
 
Discussion 
Alterations in the gut microbiota, whether causative or as a result of Type 1 diabetes, may 
have important implications for the health of people with Type 1 diabetes. The aim of this 
study was to explore gut microbiota in patients with Type 1 diabetes but good glycaemic 
control and high levels of physical fitness, matched to people without diabetes. We show for 
the first time that patients with intensively managed Type 1 diabetes with optimal glycaemic 
control and good physical fitness display gut microbiota profiles comparable with those of 
matched individuals without Type 1 diabetes. 
The gut microbiota profiles were highly individual across the whole cohort, but there is 
general conformity between the most dominant members of the community. 
Faecalibacterium sp., Roseburia sp. and Bacteroides sp. were found to be the most abundant 
in the cohort and generally represented a substantial proportion of the gut microbiota in each 
person. These species have previously been shown to be prevalent in a healthy adult gut 
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microbiota [19]. The most significant OTUs driving the separation of the Type 1 diabetes and 
control gut communities were generally low in abundance and reflected only a small 
proportion of the overall reads. For example, the Actinomyces sp. (OTU00428), which was 
the most significant OTU in the Type 1 diabetes group, compromised only 62 reads (49 reads 
from Type 1 diabetes group) from a total of 2 082 840 (0.003%). Thus, OTUs with such 
universally low relative abundance are unlikely to be contributing to disease pathophysiology 
and implying causality to disease should be avoided. Although the cohort employed in this 
study is small, with only 10 patients with Type 1 diabetes, it is comparable with that of 
previously published studies and should not influence the lack of clinically important OTUs 
discriminating people with Type 1 diabetes and controls [10]. Previous studies have also 
inferred associations at diagnosis of increasing Bacteroides and reduced Bifidobacterium in 
Type 1 diabetes [9,10]. Although these organisms were relatively abundant, overall we see 
opposing trends, with lower Bacteroides and increased Bifidobacterium in Type 1 diabetes; 
these differences are noteworthy but they were not significant, however, further work in a 
larger cohort is necessary to confirm these observations. 
The Shannon diversity index was comparable between the Type 1 diabetes and control 
groups with no significant difference found between them. Interestingly, previous studies 
suggest that children with Type 1 diabetes undergo dysbiosis of the gut microbiota, resulting 
in reduced diversity compared with people without diabetes [9,20]. The diversity reported in 
this study is comparable with that of an adult population without Type 1 diabetes, but a lack 
of published aged-matched controls prevents any comparison with adults with Type 1 
diabetes. Nonetheless, the observation that active adults with Type 1 diabetes have a similar 
diversity to adults without Type 1 diabetes is important. 
Previous studies have suggested an increase in butyrate-producing and mucin-degrading 
bacteria in controls, whereas bacteria that produce short-chain fatty acids other than butyrate 
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were higher in disease cases [21]. Thus, synthetic pathways may represent a key aetiological 
trigger in the onset of Type 1 diabetes. Functional analysis of the bacterial community in this 
dataset demonstrated comparability between the bacterial pathways of the OTUs found in 
people with Type 1 diabetes and matched controls. Despite large variation at the OTU level, 
the function profiles showed much greater comparability, as reported previously [22]. It is 
noteworthy that these functional pathways represent only those of the bacterial community 
based on the classification OTUs and thus do not account for differential gene expression 
between the two groups. 
Given the individual nature of the gut microbiota within each group of the cohort, it is 
perhaps not surprising that the ordination analysis of the bacterial profiles showed no distinct 
separation of people with Type 1 diabetes and matched controls. Thus, in adulthood, the gut 
microbiota is not significantly altered in active people as a result of being diagnosed with 
Type 1 diabetes. Notably this finding was not influenced when the Type 1 diabetes group was 
further stratified to account for ranging HbA1c. Existing comparable data are limited, with 
studies to date focusing on differences in the gut microbiota in patients at the time of 
diagnosis (i.e. childhood) [9,10]. Although the gut microbiota may serve as an environmental 
trigger in the onset of Type 1 diabetes in patients in whom genetic elements alone cannot 
account for the pathogenesis, an important finding of this study is that active adults with 
Type 1 diabetes have a gut microbiota reflective of adults without Type 1 diabetes. Further 
work should sample greater numbers of people temporally and seek to include sedentary 
patients and those with poorer glycaemic control. Future work should also consider Type 1 
diabetes patients with other pathologies, such as retinopathy or cardiovascular disease. 
Considering the lack of available data pertaining to the influence of exercise on gut 
microbiota, profiling patients across a range of glycaemic control and physical activity levels 
is warranted to ascertain whether alterations in gut microbiota are influenced by exercise, 
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glycaemic control or both, and whether intervention or therapeutic manipulation of the gut 
microbiota might confer improvements to well-being. The potential influence of differences 
in HLA genotype between those with and without Type 1 diabetes should also be considered 
in future studies. 
In summary, this study confirmed existing data relating to the dominant bacterial organisms 
in the healthy active adult gut microbiota. Importantly, we show that both gut microbiota and 
resulting functional bacterial profiles from people with long-standing Type 1 diabetes in good 
glycaemic control and high physical fitness levels are comparable with matched people 
without diabetes. 
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FIGURE 1 Bar chart of operational taxonomic units (OTUs) from Type 1 (T1) diabetes and matched controls. 
Each OTU is represented as a percentage of the total community. Samples are ordered by Faecalibacterium 
abundance. 
FIGURE 2 SIMCA analysis of Type 1 (T1) diabetes samples and matched controls (CON). (A) Principal 
components analysis (PCA) score scatter plot. R2X[1] = 0.124, R2X[2] = 0.0998. (B) Loadings plot showing 
taxa associated with each group. Green (Y) represents each operational taxonomic unit (OUT) detected, where 
only the significantly different OTUs between cases and controls are labelled. Blue (X) shows different 
classification of the model, where OTUs associated with control samples are shown on the upper right and 
OTUs associated with cases are shown on the lower left. 
FIGURE 3 Bar chart of phylogenetic investigation of communities by reconstruction of unobserved states 
(PICRUSt) analysis from Type 1 diabetes and matched controls. Each function is represented as a percentage of 
the total community. Samples are ordered in accordance with Fig. 1. 
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Supporting Information 
Additional Supporting Information is available in the online version of this article: 
Figure S1. PCA analysis of Type 1 diabetes (T) samples and matched controls (C), with the 
Type 1 diabetes group split to account for differing glycaemic control. 
 
Table 1 Individual participant characteristics 
Group 
Subject 
ID 
Age 
(years) BMI 
VO2peak 
(ml/kg/min) 
Fasting blood 
glucose (mmol/l) 
Diabetes 
duration 
(years) 
HbA1c 
(mmol/mol) 
Control C1 25 22.1 50 4.20
C2 23 21.4 51 4.32
C3 31 21.7 56 4.33 
C4 30 20.1 52 3.87 
C5 28 26.9 48 3.46
C6 26 21.4 55 4.02
C7 26 23.7 50 3.29 
C8 30 25.4 51 4.22 
C9 25 21.8 45 4.28
C10 26 20.4 49 4.22
Type 1 
diabetes 
T1 29 22.8 57 5.44 5 54 
T2 24 25.9 48 5.75 11 42 
T3 19 22.5 64 5.01 12 49 
T4 34 22.4 50 3.90 5 60 
T5 21 22.5 56 8.43 12 55 
T6 33 27.1 52 7.32 19 58 
T7 29 26.9 41 6.45 5 58 
T8 25 22.8 51 6.31 24 43 
T9 24 22.4 45 3.45 13 50 
T10 31 22.5 46 3.22 19 61 
VO2peak, peak oxygen uptake. Between-group comparisons assessed with independent samples t-test. 
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Table 2 Operational taxonomic units (OTUs) that differ significantly between patients with Type 1 diabetes and 
matched controls 
Group 
P-
val
ue 
OTU Phylum Class Order Family Genus 
Control 0.003 
OTU0
0082 Firmicutes Clostridia 
Clostridial
es 
Lachnospira
ceae Unclassified 
Control 0.017 
OTU0
1214 Firmicutes Bacilli Bacillales 
Bacillaceae_
1 Anoxybacillus 
Control 0.019 
OTU0
0865 Proteobacteria 
Alphaproteo
bacteria 
Rhizobiale
s 
Aurantimona
daceae Aurantimonas 
Control 0.021 
OTU0
0820 
Deinococcus-
Thermus Deinococci 
Deinococc
ales 
Deinococcac
eae Deinococcus 
Control 0.026 
OTU0
0625 Firmicutes Clostridia 
Clostridial
es 
Clostridiacea
e_1 
Clostridium_sens
u_stricto 
Control 0.027 
OTU0
0217 Firmicutes Clostridia 
Clostridial
es 
Lachnospira
ceae Coprococcus 
Control 0.027 
OTU0
0230 Proteobacteria 
Betaproteoba
cteria 
Burkholder
iales Unclassified Unclassified 
Control 0.032 
OTU0
0807 Proteobacteria 
Betaproteoba
cteria 
Burkholder
iales 
Comamonad
aceae Schlegelella 
Control 0.033 
OTU0
1323 Proteobacteria 
Betaproteoba
cteria 
Burkholder
iales Unclassified Unclassified 
Control 0.036 
OTU0
1060 Actinobacteria 
Actinobacter
ia 
Coriobacte
riales 
Coriobacteri
aceae Unclassified 
Control 0.039 
OTU0
0363 Proteobacteria 
Betaproteoba
cteria 
Rhodocycl
ales 
Rhodocyclac
eae Zoogloea 
Control 0.041 
OTU0
0384 Proteobacteria 
Betaproteoba
cteria 
Burkholder
iales 
Comamonad
aceae Unclassified 
Type 1dia
betes 
0.0
08 
OTU0
0428 Actinobacteria 
Actinobacter
ia 
Actinomyc
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Unclassified;Poorly Characterized
Unclassified;Metabolism
Unclassified;Genetic Information Processing
Unclassified;Cellular Processes and Signaling
Organismal Systems;Nervous System
Organismal Systems;Immune System
Organismal Systems;Excretory System
Organismal Systems;Environmental Adaptation
Organismal Systems;Endocrine System
Organismal Systems;Digestive System
Organismal Systems;Circulatory System
Metabolism;Xenobiotics Biodegradation and Metabolism
Metabolism;Nucleotide Metabolism
Metabolism;Metabolism of Terpenoids and Polyketides
Metabolism;Metabolism of Other Amino Acids
Metabolism;Metabolism of Cofactors and Vitamins
Metabolism;Lipid Metabolism
Metabolism;Glycan Biosynthesis and Metabolism
Metabolism;Enzyme Families
Metabolism;Energy Metabolism
Metabolism;Carbohydrate Metabolism
Metabolism;Biosynthesis of Other Secondary Metabolites
Metabolism;Amino Acid Metabolism
Human Diseases;Neurodegenerative Diseases
Human Diseases;Metabolic Diseases
Human Diseases;Infectious Diseases
Human Diseases;Immune System Diseases
Human Diseases;Cardiovascular Diseases
Human Diseases;Cancers
Genetic Information Processing;Translation
Genetic Information Processing;Transcription
Genetic Information Processing;Replication and Repair
Genetic Information Processing;Folding, Sorting and Degradation
Environmental Information Processing;Signaling Molecules and Interaction
Environmental Information Processing;Signal Transduction
Environmental Information Processing;Membrane Transport
Cellular Processes;Transport and Catabolism
Cellular Processes;Cell Motility
Cellular Processes;Cell Growth and Death
 
